WELLESLEY HILLS, Massachusetts, May 26 /PRNewswire/ --
Joseph F. Finn, Jr., C.P.A. (Finn), announced today that there has been promising initial interest from pharma companies in the intellectual property of Prospect Therapeutics, Inc. (Prospect).
In preclinical studies, GCS-100 inhibited blood vessel formation in a variety of cancer models. Development and growth of solid tumors requires new blood vessel growth, or angiogenesis, to deliver oxygen and nutrients to a tumor. Galectin-3 also plays an important role in stimulating angiogenesis in a variety of tissues.
The intellectual property, regulatory dossier, fixed assets and clinical inventory will be sold at auction on Monday, June 29, 2009 at 12:00 noon.